Prantik Das

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Patient Reported Outcomes

Cross Sectional

Prostate Cancer

Small Cell Lung Cancer

Top Venues

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Nicholas D James, Noel W Clarke, Adrian D Cook, Adnan Ali, Alex P Hoyle, Gerhardt Attard, Christopher D Brawley, Simon Chowdhury, William R Cross, David P Dearnaley, Johann S de Bono, Carlos Diaz-Montana, Duncan C Gilbert, Silke Gillessen Sommer, Clare Gilson, Robert J Jones, Ruth E Langley, Zafar I Malik, David J Matheson, Robin Millman, Chris C Parker, Cheryl Pugh, Hannah L Rush, J Martin Russell, Dominik R Berthold, Michelle L Buckner, Malcolm D Mason, Alastair W S Ritchie, Alison Jane Birtle, Susannah J Brock, Prantik Das, Dan Ford, Joanna Gale, Warren Grant, Emma K Gray, Peter J Hoskin, Mohammad M Khan, Caroline Manetta, Neil J McPhail, Joe M O'Sullivan, Omi Parikh, Carla Perna, Carmel J Pezaro, Andrew S Protheroe, Angus J Robinson, Sarah M Rudman, Denise J Sheehan, Narayanan N Srihari, Isabel Syndikus, Jacob S Tanguay, Carys W Thomas, Salil Vengalil, John Wagstaff, James P Wylie, Mahesh K B Parmar, Matthew Robert Sydes, null null
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). International journal of cancer 151 (3) (2022)
Heather Ann Payne, Suneil Jain, Clive Peedell, Albert Edwards, James Andrew Thomas, Prantik Das, Amanda Hansson Hedblom, Emily Woodward, Rhodri Saunders, Amit Bahl
Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK. BMJ open 12 (7) (2022)
Prantik Das, Sarah Taylor, James Price, Michael Jones, Cristina Martin-Fernandez, Akram Ali, Thangrarajh Mugunthan, Chandrani Mallik, Colin Ward
Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). BJUI compass 1 (1) (2020)